

<b>The Biology and Natural History of Prostate Cancer: A Short Introduction</b> . . . . .	1
Lars Holmberg and Mieke Van Hemelrijck	
<b>Germline Genetic Variants Associated with Prostate Cancer and Potential Relevance to Clinical Practice</b> . . . . .	9
Chee Leng Goh and Rosalind Anne Eeles	
<b>Lifestyle and Dietary Factors in Prostate Cancer Prevention</b> . . . . .	27
Andrea Discacciati and Alicja Wolk	
<b>Nutrition, Hormones and Prostate Cancer Risk: Results from the European Prospective Investigation into Cancer and Nutrition</b> . . . . .	39
Timothy J. Key	
<b>Screening for Prostate Cancer: Current Status of ERSPC and Screening-Related Issues</b> . . . . .	47
Fritz H. Schröder	
<b>Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial</b> . . . . .	53
Gerald L. Andriole	
<b>ERSPC, PLCO Studies and Critique of Cochrane Review 2013</b> . . . . .	59
Fritz H. Schröder	
<b>Screening for Prostate Cancer: Reflecting on the Quality of Evidence from the ERSPC and PLCO Studies</b> . . . . .	65
Dragan Ilic	

<b>Phase III Prostate Cancer Chemoprevention Trials</b> . . . . .	73
Howard L. Parnes, Otis W. Brawley, Lori M. Minasian and Leslie G. Ford	
<b>Risk Adapted Chemoprevention for Prostate Cancer: An Option?</b> . . .	79
Bernd J. Schmitz-Dräger, Oliver Schöffski, Michael Marberger, Sevim Sahin and Hans-Peter Schmid	
<b>Aspirin and Prostate Cancer Prevention</b> . . . . .	93
Cristina Bosetti, Valentina Rosato, Silvano Gallus and Carlo La Vecchia	
<b>Chemoprevention of Prostate Cancer by Isoflavonoids</b> . . . . .	101
Stefan Aufderklamm, Florian Miller, Anastasia Galasso, Arnulf Stenzl and Georgios Gakis	
<b>Lycopene for the Prevention and Treatment of Prostate Disease</b> . . . .	109
Dragan Ilic	
<b>Chemoprevention of Prostate Cancer with the Polyamine Synthesis Inhibitor Difluoromethylornithine</b> . . . . .	115
Frank L. Meyskens Jr., Anne R. Simoneau and Eugene W. Gerner	
<b>Prostate Cancer Prevention: Agent Development Strategies</b> . . . . .	121
Howard L. Parnes, Margaret G. House and Joseph A. Tangrea	
<b>Prognostic Value of a Cell Cycle Progression Score for Men with Prostate Cancer</b> . . . . .	133
Jack Cuzick	
<b>Distinguishing Indolent from Aggressive Prostate Cancer</b> . . . . .	141
Zoran Culig	
<b>Management of Low Risk and Low PSA Prostate Cancer: Long Term Results from the Prostate Cancer Intervention Versus Observation Trial</b> . . . . .	149
Timothy J. Wilt	